Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesEffect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis
Clinical Therapeutics, 10/29/09
Kampmann C et al. – Treatment with agalsidase alfa for 12 or 36 months was associated with reduced LVM in these patients with Fabry disease with baseline LVH, and it appeared to stabilize LVM in these patients without baseline LVH.
Related Articles
A case of minimal change disease in a Fabry patient
Pediatric Nephrology, 11/04/09
Relevance Score: 88%
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL? for Fabry Disease with U.S. FDA
Shire, 10/22/09
Relevance Score: 88%
Genetics: Hypertrophic cardiomyopathy
Canadian Family Physician, 11/16/09
Relevance Score: 87%
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09
Relevance Score: 81%
Hormone replacement therapy benefits postmenopausal women
Internet Source, 10/09/09
Relevance Score: 81%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor